Cue Biopharma Reports First Quarter 2023 Financial Resu

BOSTON, May 09, 2023 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T... | May 9, 2023

Related Keywords

United States , Massachusetts , Boston , American , Patrick Verheyen , Pamelad Garzone , Daniel Passeri , Matteo Levisetti , Marie Campinell , Rafi Ahmed , Twitter , Nasdaq , Corporate Communications , Cue Biopharma Inc , Securities Exchange , Drug Administration , American Society Of Clinical Oncology , Ono Pharmaceutical Co Ltd , Clinical Oncology , Annual Meeting , Ono Pharmaceutical , Chief Medical Officer , Cue Biopharma , Consolidated Statement , Selective Targeting , Securities Act , Securities Exchange Act , Risk Factors , Financial Condition , Annual Report , Quarterly Report , Nc Stock Exchange , News , Information , Press Release , Bay , 023 , Ue , Iopharmaceutical , Company , Developing , Novel , Glass , F , Injectable , Iologics , O , Selectively , Ngage , End , Odulate Cue Us22978p1066 ,